/
ANRO
$28.07+$1.03 (+3.81%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$948.9M
35M shares
52-week range
$2.15 – $28.44
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$7.37
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $210.0K | $0 | $0 | $0 | $0 |
| Cost of revenue | $145.0K | $342.0K | $0 | $502.0K | $661.0K |
| Gross profit | $65.0K | −$342.0K | $0 | −$502.0K | −$661.0K |
| Gross margin | 31.0% | — | — | — | — |
| R&D | $8.4M | $23.7M | $30.3M | $47.0M | $45.6M |
| Operating income | −$12.1M | −$29.2M | −$37.8M | −$68.6M | −$66.4M |
| EBITDA | −$9.0M | −$27.4M | −$34.6M | −$62.3M | −$60.1M |
| Net income | −$9.2M | −$27.7M | −$36.3M | −$61.4M | −$63.2M |
| Net margin | -4374.8% | — | — | — | — |
| EPS (diluted) | -0.36 | -1.08 | -1.35 | -2.50 | -2.19 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-3.00 | $-4.14–$-2.24 | 8 |
| 2027 | $0 | $-3.23 | $-4.94–$-2.13 | 8 |
| 2028 | $6M | $-3.28 | $-4.81–$-2.11 | 7 |
| 2029 | $56M | $-2.85 | $-2.85–$-2.85 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5.91
Price
$28.07
Implied downside
-79%
Peer comparison
Alto Neuroscience Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
www.altoneuroscience.com- Employees
- 68
- IPO / List date
- Feb 2, 2024
- HQ
- MOUNTAIN VIEW, CA
Held by traders on TradeandTell
No one on the platform currently holds ANRO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 103,499 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANRO yet.
